The global hemophilia treatment market is forecast to reach USD 12.1 billion in 2024. Between 2024 and 2034, hemophilia treatment is predicted to register a CAGR of 4.4%. Worldwide, the hemophilia treatment market is expected to reach USD 18.7 billion by 2034.
The disease hemophilia is characterized by a loss of clotting proteins in the blood, resulting in life-threatening bleeding. As a preventative treatment, regular injections of clotting factors can also benefit people with hemophilia A. A reduction in excessive bleeding and a reduction in bleeding unnecessarily can be achieved by this method.
Get your PDF Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-14324
Hemophilia can be treated with component replacements derived from human plasma and recombinant products. With these remedies, the clotting aspect in the body is increased, which leads to better clotting and less bleeding.
Prophylactic or episodic treatment merchandise is commonly prescribed by healthcare providers. Bleeding episodes can be prevented with episodic care while bleeding episodes can be prevented with prophylactic care. Hemophilia patients can prevent and treat bleeding episodes more effectively and efficiently if they can perform infusions at home.
Hemophilia can be treated with gene therapy, which is an area of ongoing research. Hemophilia A and hemophilia B gene therapy treatments have been approved by the FDA in recent years. Hemophilia individuals may be able to benefit from genetic treatments that can provide the missing clotting factors for a long time to come.
“Advancements in treatment and revolutionary approaches to gene therapies have driven hemophilia treatment demand to unprecedented heights. Developments in diagnostics and ongoing developments in hemophilia treatments are expected to expand the market for hemophilia treatments in years ahead.” – Says an analyst at FMI.
Key Takeaways from the Hemophilia Treatment Market:
- Historically, hemophilia treatment generated a 4.1% CAGR from 2019 to 2023.
- Through 2034, the United States and Canada market is expected to experience a CAGR of 2%.
- It is anticipated that India will exhibit a CAGR of 7.4% during the forecast period.
- Between 2024 and 2034, China’s market is expected to expand at a CAGR of 6.5%.
- Based on drug class, prophylaxis accounted for 68.7% of the market in 2023.
Request Customization of the Report: https://www.futuremarketinsights.com/customization-available/rep-gb-14324
Competitive Landscape:
Hemophilia treatment companies are actively investing in research and development in order to introduce novel therapies to the global market. As part of their growth strategy, these companies are implementing acquisitions, mergers, product developments and approvals, collaborative ventures, etc.
Recent Development:
- In February 2023, Octapharma USA filed a Biologics License Application Supplement (sBLA) to the U.S. Food and Drug Administration (FDA) expanding the approval of wilate®, von Willebrand Factor/Coagulation Factor VIII Complex (Human) Lyophilized Powder for Solution for Intravenous Injection, aimed at reducing bleeding in children and adults with von Willebrand disease (VWD).
- In December 2023, Global biotechnology leader CSL released its three-year results for its pivotal HOPE-B study, showing that HEMGENIX® (etranacogene dezaparvovec-drlb) was effective in treating hemophilia B in patients who received a one-time infusion. At the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, data showing that one-time infusions of HEMGENIX increase factor IX activity levels for years were presented.
Key Players of the Hemophilia Treatment Industry:
- Hoffmann-La Roche Ltd
- Octapharma
- CSL Behring
- Sanofi
- Bayer AG
- Baxter
- Swedish Orphan Biovitrum AB
- Grifols International S.A
- Kedrion
A Full Report on Market: https://www.futuremarketinsights.com/checkout/14324
Hemophilia Treatment Market Segmentation
By Drug Class:
In terms of drug class, the industry is divided into clotting factors (recombinant factor concentrates, plasma-derived factors concentrate), monoclonal antibodies, antidiuretic and antihemorrhagic drugs, aminocaproic acid, antifibrinolytic agents, and gene therapy.
By Indication:
In terms of indication, the industry is segregated into a hemophilia A, hemophilia B, and Von Willebrand disease.
By Distribution Channel:
In terms of distribution channel, the industry is segmented into hospitals, specialized clinics, retail pharmacies, and mail order pharmacies.
By Region:
Key countries of North America, Latin America, Western Europe, Eastern Europe, South Asia, East Asia, Middle East, and Africa have been covered in the report.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
